StrideBio is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies. The company is building a proprietary therapeutic pipeline focused on rare diseases.
Company (Alive / Active)
701 West Main Street
North Carolina, United States
|Investor||Investor Type||Location||Participating Rounds|
|San Francisco, California, United States||IPO / Went public||Audentes is a biotechnology company committed to the development and commercialization of treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).||Login to see details|
|Title||Application Date||Patent Date||Status
(Patent / Application)